

Name of instrument	Type of respondent	Est. number of respondents per year	Instruments completed per respondent	Time burden per instrument (minutes)	Total burden per instrument (hours)
Patient Demographics	Patient	4,780	1	3	239
Patient Post Session	Patient	4,780	1	7	558
Provider Demographics	All providers (filled out once)	2,390	1	2	80
Consult Initiator Information	Provider who requested TM consult	1,195	4	4	319
Consult Initiator Satisfaction	Provider who requested TM consult	1,195	4	4	319
Provider Post Session	Consulting provider	1,195	4	4	319
Consult Recipient Satisfaction	Consulting provider	1,195	4	5	398
Session Information (Consulting Site)	Site coordinator (consulting site)	20	240	6	480
Session Information (Primary Care Site) ..	Site coordinator (primary care site)	300	16	2	160
Emergency/Triage Encounter (Consulting Site).	Emergency room staff person	15	10	4	10
Emergency/Triage Encounter (Originating Site).	Emergency room staff person	15	10	4	10
Provider Satisfaction (Periodic)	All providers (filled out every 4 months) ..	2,390	3	3	359
System information	Program administrator/technical staff	320	2	25	267
Program Costs	Program administrator	320	1	25	133
Total		8,160			3651

Send comments to Patricia Royston, HRSA Reports Clearance Officer, Room 14-36, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: June 16, 1997.

James J. Corrigan,

Acting Associate Administrator for Management and Program Support.

[FR Doc. 97-16128 Filed 6-18-97; 8:45 am]

BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: A RCT of Plant-Based Diet in Breast Cancer Recurrence.

Date: July 14, 1997.

Time: 2:00 p.m.

Place: Teleconference, National Cancer Institute, Division of Extramural Activities, Grants Review Branch, 6130 Executive Boulevard, EPN-Room 635, Bethesda, MD 20892.

Contact Person: Maureen Johnson, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 635F 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892-7410, Telephone: 301/496-7565.

Purpose/Agenda: To evaluate and review grant application.

The meeting will be closed in accordance with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: June 13, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-16016 Filed 6-18-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meetings:

Name of SEP: Career Development and Mentored Peer Review.

Date: July 25, 1997.

Time: 8:30 a.m. to 5:00 p.m.

Place: Executive Plaza North, Conference Room E, 6130 Executive Boulevard, Rockville, MD 20852.

Contact Person: Wilma Woods, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North,

Room 622, 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892-7410, Telephone: 301/496-7903.

Purpose/Agenda: To evaluate and review grant applications.

Name of SEP: Polyvalent Vaccine: Phase III Trial in Phase IV Melanoma.

Date: August 5, 1997.

Time: 10:30 a.m.-Adjournment.

Place: Holiday Inn-Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20817.

Contact Person: Harvey P. Stein, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 611B, 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892-7410, Telephone: 301/496-7481.

Purpose/Agenda: To evaluate and review a grant application.

These meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: June 13, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-16018 Filed 6-18-97; 8:45 am]

BILLING CODE 4140-01-M